Construction & cities

Kazakhstan: Government approves ₸173 billion investments in four pharmaceutical production sites

Investors, volumes and stages of the region's major projects – for European suppliers

· 5 Sources

Scroll
Construction & cities Kazakhstan5 Sources

Published · last updated · 21 Jan 2026 – 23 Jan 2026

The government of Kazakhstan has approved investment agreements between the Ministry of Healthcare and four pharmaceutical companies. The projects, with a total volume of ₸173 billion, aim to localize the production of 356 types of medicines. The sites are located in Almaty and the Almaty and Turkestan regions.

Approval of Investment Agreements

The government of Kazakhstan has approved the conclusion of investment agreements between the Ministry of Healthcare and four pharmaceutical companies. The corresponding government resolutions were signed by Prime Minister Olzhas Bektenov. The implementation is carried out as part of the instructions of President Kassym-Jomart Tokayev to increase the share of domestic production in the pharmaceutical industry. The total investment volume amounts to ₸173 billion.

Production Scope and Location Distribution

The projects will localize the production of 356 types of medicines, including socially significant drugs. The portfolio includes treatments for oncological diseases and diabetes mellitus, as well as immunobiological, antiviral, anti-anemic, analgesic, anti-inflammatory, anti-cold, and antimicrobial medicines. The new facilities are being built in the city of Almaty (two projects) and in the Almaty and Turkestan regions.

AltINFARM LLP Project

AltINFARM LLP plans to build a pharmaceutical plant in the Special Economic Zone "Park of Innovative Technologies" in Almaty. The investment volume is ₸58.5 billion. The production of 54 medicines is planned, including 35 socially significant drugs, focusing on immunobiological products and treatments for oncology and diabetes. The project creates around 60 new jobs. Strategic partners are Sinopharm, Sinovac, and Kangtai Biological Technology.

Nobel Almaty Pharmaceutical Factory JSC Project

Nobel Almaty Pharmaceutical Factory JSC is constructing a complex in Almaty for the production of active pharmaceutical ingredients, finished medicines, and biopharmaceuticals in compliance with international GMP standards. Investments amount to ₸39.2 billion. The facility will produce 53 medicines, 17 of which are socially significant. At least 200 jobs will be created. The strategic partner is Nobel İlaç.

Abdi Ibrahim and MSP-ROMPHARM Projects

Abdi Ibrahim Global Pharm LLP is building a multi-profile complex in the Almaty region with investments of ₸39 billion for 76 medicines, including antivirals and type II diabetes treatments. At least 150 jobs will be created; the partner is Abdi Ibrahim. MSP-ROMPHARM LLP is building a facility in the TURAN Special Economic Zone (Turkestan region) and in the Almaty region with a total investment of ₸36.7 billion for 101 medicine types. Approximately 265 jobs will be created; partners are World Medicine and Rompharm.

Project: Localization of pharmaceutical production in Kazakhstan · Kazakhstan · Planned · $370 m

Key facts

  • Total investment volume: ₸173 billion
  • Number of medicine types to be localized: 356
  • New jobs created: approx. 675
  • Locations: Almaty, Almaty Region, Turkestan Region
  • Participating companies: AltINFARM LLP, MSP-ROMPHARM LLP, Abdi Ibrahim Global Pharm LLP, Nobel Almaty Pharmaceutical Factory JSC
  • Resolutions signed by: Prime Minister Olzhas Bektenov

All sources (6)

  1. Четыре новых фармацевтических завода построят в КазахстанеVlast.kz · · RU
  2. В Казахстане построят четыре фармацевтических заводаForbes.kz · · RU
  3. Реализация поручений Президента: в Казахстане построят четыре новых фармзаводаPrimeMinister.kz · · RU
  4. Implementation of the President’s Instructions: Four New Pharmaceutical Plants to Be Built in KazakhstanPrimeMinister.kz · · EN
  5. Kazakhstan to invest 173 billion in pharmaceutical production: what medicines will be made locallyDKNews.kz · · EN
  6. Kazakhstan Approves $370 Million in Investments to Localize Pharmaceutical ProductionThe Astana Times · · EN

Imprint | Information pursuant to § 5 DDG

Company

AETEK GmbH Lindenstraße 5
63808 Haibach, Germany

Managing Director

Artur R. Pamin

Commercial Register

Amtsgericht Aschaffenburg
HRB 14157

VAT ID No.

DE288091462

EORI No.

DE644795536634916

Scan · LinkedIn